Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | DHFR | P00374 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8390658 | 0.81 | SLC2A1 (0.49) | SLC2A1DHFRKCNH2 | |
| SCHEMBL8348805 | 0.79 | DHFR (0.46) | SLC2A1DHFRKCNH2DCPS | |
| SCHEMBL24343804 | 0.77 | DHFR (0.50) | SLC2A1DHFR | |
| SCHEMBL27310014 | 0.76 | DHFR (0.44) | DHFRKCNH2DCPS | |
| SCHEMBL8389989 | 0.76 | DCPS (0.51) | SLC2A1DHFRKCNH2DCPS | |
| SCHEMBL8387576 | 0.74 | DHFR (0.45) | SLC2A1DHFR | |
| SCHEMBL8389944 | 0.74 | SLC2A1 (0.44) | SLC2A1DHFRDCPS | |
| SCHEMBL9575141 | 0.73 | DHFR (0.46) | SLC2A1DHFRKCNH2DCPS | |
| SCHEMBL30912751 | 0.72 | DHFR (0.66) | DHFRKCNH2DCPS | |
| SCHEMBL8390061 | 0.72 | DHFR (0.66) | DHFRKCNH2DCPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019055754-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2018204764-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20160058749-A1 | TREATMENTS FOR NEUROPATHY | CHILDRENS MEDICAL CENTER (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160045487-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-18 | — | — | US | disclosed |
| US-20090203735-A1 | TREATMENTS FOR NEUROPATHY | NIH-DEITR | 2009-08-13 | — | — | US | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-5874579-A | Insecticidal substituted-2.4-diaminoquinazolines related applications | FMC CORPORATION (US) | 1999-02-23 | — | — | US | disclosed |
| US-5616718-A | USEFUL FOR MAKING 2,4-DIAMINOQUINAZOLINES; INSECTICIDES | FMC CORPORATION (US) | 1997-04-01 | — | — | US | disclosed |
| US-5534518-A | Insecticidal substituted-2,4-diaminoquinazolines | FMC CORPORATION (US) | 1996-07-09 | — | — | US | disclosed |
| EP-0684824-A4 | INSECTICIDAL SUBSTITUTED-2,4-DIAMINOQUINAZOLINES. | FMC CORP (US) | 1996-02-14 | — | — | EP | disclosed |
| EP-0684824-A1 | INSECTICIDAL SUBSTITUTED-2,4-DIAMINOQUINAZOLINES | FMC CORPORATION (US) | 1995-12-06 | — | — | EP | disclosed |
| WO-1994018980-A1 | INSECTICIDAL SUBSTITUTED-2,4-DIAMINOQUINAZOLINES | FMC CORPORATION (US) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058749-A1 | TREATMENTS FOR NEUROPATHY | NGF, BDNF, NTRK2 | SLC2A1 841/4885DHFR 955/4885KCNH2 1523/4885 |
| US-20090203735-A1 | TREATMENTS FOR NEUROPATHY | NGF, BDNF, NTRK2 | SLC2A1 841/4885DHFR 955/4885KCNH2 1523/4885 |
| US-20160045487-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | PMP22, GAP43, NGF | SLC2A1 2867/4885DHFR 2588/4885KCNH2 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.